Filing Flows › Zevra Therapeutics (ZVRA) › Q4 2025
Zevra Therapeutics (ZVRA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Zevra Therapeutics (ZVRA) reported revenue of $34.1M for the fourth quarter 2025 (Q4 2025), +183% from a year earlier and +31% from the quarter before. Operating margin was 27.3%, net earnings $12.2M (35.6% of revenue).
Zevra Therapeutics, Q4 2025: revenue $34.1M (+183% year over year), operating margin 27.3%, net earnings $12.2M, operating cash flow $5.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34.1M | +31% | +183% |
| Operating profit | $9.3M | +125% | — |
| Net earnings | $12.2M | — | — |
| Operating cash flow | $5.5M | +17% | — |
What changed
Revenue was $34.1M in Q4 2025, up 183% year over year and up 31% from the previous quarter.
Operating profit was $9.3M, a 27.3% margin (up 155.3 points year over year). Total costs fell 10% while revenue rose 183%. The fastest-growing cost line was SG&A (+26%). Net earnings were $12.2M. The effective tax rate was 4.0%. Non-operating items added $3.4M, 26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $5.5M, 45% of net earnings. Non-cash charges added back $362K of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items used $11.3M. Capital expenditures of −$31K left free cash flow of $5.5M.
Questions
What was Zevra Therapeutics' revenue in the fourth quarter 2025?
Zevra Therapeutics (ZVRA) reported revenue of $34.1M for the fourth quarter 2025 (Q4 2025), +183% from a year earlier and +31% from the quarter before.
Was Zevra Therapeutics profitable in the fourth quarter 2025?
Operating profit was $9.3M (27.3% of revenue) and net earnings $12.2M.
Source: Zevra Therapeutics 10-K on SEC EDGAR.